Comprehensive Review on Analytical and Bioanalytical Methods for Quantification of Anti-angiogenic Agents used in Treatment of Cervical Cancer

Cervical cancer is one of the most prevalent forms of cancer occurring across the world and it has been observed that about 99.7% of cervical cancer cases occur due to infections with the Human papillomavirus (HPV). Over prolonged durations, cervical cancer can lead to complications such as vaginal bleeding, itching, and in more severe instances, even the fatality of the individual. Cervical cancer is an essential cause of death at an early age as it affects young women higher than other populations. The most frequent drugs used in its treatment include antiangiogenic drugs. This review summarizes analytical techniques used for the quantification of anti-angiogenic agents- Bevacizumab, Sunitinib, Pazopanib, Brivanib, and Imatinib. Furthermore, an in-depth description of numerous techniques including NIR (1), HPLC (10), LC-MS (28), and HPTLC (1) approaches used to determine and quantify these agents have been provided in this review. Based on the matrix utilized, the following details were discussed: analytical conditions, detection limits, and solvent used in sample preparation. Our review holds significant importance within the scientific community, offering valuable insights into commonly employed measurement techniques and the latest advancements in these approaches.